Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Parallel-design Clinical Study to Evaluate the Irritable Bowel Syndrome Symptoms Improving Effect and Safety of Lactobacillus Plantarum APsulloc 331261(GTB1)
Conditions
Interventions
GTB1
Placebo
Locations
1
South Korea
Amorepacific
Yongin-si, Gyeonggi-do, South Korea
Start Date
November 1, 2020
Primary Completion Date
December 31, 2020
Completion Date
January 29, 2022
Last Updated
May 17, 2022
NCT07103772
NCT03729271
NCT04855799
NCT03806959
NCT05130047
NCT05339243
Lead Sponsor
Amorepacific Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions